Conflicting evidence exists with ICI therapies in other malignancies, for example, in HER-2 + gastric cancer, ICI in combination with chemotherapy and trastuzumab (anti HER-2 mAB) in the KEYNOTE-811 phase 3 trial demonstrated an ORR of 74.4% (95% CI, 66.2–81.6) in the pembrolizumab arm and 51.9% (95% CI, 43.0–60.7) in the placebo arm [88]. The gene discussed is ERBB2; the disease is gastric cancer.